These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2361314)

  • 1. Changes of antithrombin III and antithrombin III-heparin complex levels, and ACT in cardiac surgery.
    Inada E; Iwahashi K; Aoki K; Takanashi S; Kohama M; Aoki Y
    Can J Anaesth; 1990 May; 37(4 Pt 2):S75. PubMed ID: 2361314
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of blood loss and heparin rebound following cardiopulmonary bypass.
    Pifarre R; Sullivan HJ; Montoya A; Bakhos M; Grieco J; Foy BK; Blakeman B
    Semin Thromb Hemost; 1989 Apr; 15(2):173-7. PubMed ID: 2787532
    [No Abstract]   [Full Text] [Related]  

  • 3. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
    Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
    Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How much dosage of heparin do you administer? The relationship between heparin dosage and activated coagulation time (ACT) value during cardiovascular surgery: a multi center investigations].
    Shibasaki M; Nakajima Y; Kojima A; Kitagawa H; Tanimoto K; Mizobe T
    Masui; 2010 Apr; 59(4):535-9. PubMed ID: 20420155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass.
    Barnette RE; Shupak RC; Pontius J; Rao AK
    Anesth Analg; 1988 Jan; 67(1):57-60. PubMed ID: 3257361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma heparin levels during extracorporeal circulation and their significance].
    Taniguchi K; Ujihara Y; Miyamoto M; Miyako M; Hayano Y; Noguchi T; Honda N; Hadama T; Shirabe J
    Masui; 1986 Apr; 35(4):616-22. PubMed ID: 3747107
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heparin management by activated coagulation time during cardiopulmonary bypass].
    Shikano K; Shinpo H; Nasu M; Morimoto T; Suzuki T; Yada I; Kusagawa M
    Kyobu Geka; 1981; 34(12):934-7. PubMed ID: 7349352
    [No Abstract]   [Full Text] [Related]  

  • 11. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays.
    Savidge GF; Kesteven PJ; Al-Hasani SF; O'Brien PF
    Thromb Haemost; 1983 Oct; 50(3):745-8. PubMed ID: 6648894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heparin resistance during cardiopulmonary bypass].
    Maeda R; Fukuda H; Nakaigawa Y; Hiruta M; Hirabayashi Y; Seo N
    Masui; 2003 Sep; 52(9):1003-5. PubMed ID: 14531265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
    Zaidan JR; Johnson S; Brynes R; Monroe S; Guffin AV
    Anesth Analg; 1986 Apr; 65(4):377-80. PubMed ID: 3954111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Mar; 85(3):346-53. PubMed ID: 6827843
    [No Abstract]   [Full Text] [Related]  

  • 16. [Our method and concept concerning the activated clotting time (ACT) during cardiopulmonary bypass].
    Watanabe T; Abe T; Iyomasa Y
    Kokyu To Junkan; 1983 Jul; 31(7):781-6. PubMed ID: 6658213
    [No Abstract]   [Full Text] [Related]  

  • 17. The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald DJ; Patel A; Body SC; Garvin S
    Perfusion; 2009 Mar; 24(2):93-6. PubMed ID: 19654150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?
    Rodríguez-López JM; del Barrio E; Lozano FS; Muriel C
    Anesth Analg; 2008 Oct; 107(4):1444-5. PubMed ID: 18806070
    [No Abstract]   [Full Text] [Related]  

  • 20. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.